07 Dec Gary Bloomgren
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_separator type="transparent" thickness="30" up="50" down="50"][/vc_column][/vc_row][vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="1/4"][vc_single_image image="146" img_size="full" style="vc_box_border_circle_2" border_color="white" qode_css_animation=""][vc_separator type="transparent" thickness="10" up="10" down="10"][vc_column_text] Gary Bloomgren, M.D. Executive Director Amylin Pharmaceuticals, Inc. [/vc_column_text][/vc_column][vc_column width="3/4"][icons icon="fa-quote-right" size="fa-3x" type="normal" position="right" target="_self" icon_color="#ffffff"][vc_column_text]The Sherpa program has enabled...